| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/21/2005 | CN1671371A Combination of an aromatase inhibitor with a bisphosphonate |
| 09/21/2005 | CN1671370A Composition for solubilization of paclitaxel and preparation method thereof |
| 09/21/2005 | CN1671351A NSAID-containing topical formulations that demonstrate chemopreventive activity |
| 09/21/2005 | CN1670208A Cancer-inhibiting gene and its application in preparing anticancer medicine combined with chemical therapeutic medicine |
| 09/21/2005 | CN1670035A Endothelium chalone capable of improving antitumor activity with changed structure and its use |
| 09/21/2005 | CN1670032A Human telomerase active inhibitor protein and use thereof |
| 09/21/2005 | CN1670009A Propynyl or dienyl biaromatic compounds |
| 09/21/2005 | CN1669585A Tumor therapeutic agent and usage thereof |
| 09/21/2005 | CN1669563A Tumour paste and preparation method thereof |
| 09/21/2005 | CN1669560A Application of ferriferrous oxide particle in preparation of tumour heating treatment auxiliary drug |
| 09/21/2005 | CN1669558A Medicinal composition containing panax ginseng polysaccharide |
| 09/21/2005 | CN1219881C Human protooncogene and protein encoded therein |
| 09/21/2005 | CN1219796C Application of N-end amino acid of interferon-tau polypeptide |
| 09/21/2005 | CN1219791C Process for preparing panaxoside Rk1 and Rg5 by panaxadiol type saponins acid hydrolysis |
| 09/21/2005 | CN1219780C Heterocyclic compounds binding chemotactic factor receptor |
| 09/21/2005 | CN1219768C Quinoline derivatives as inhibitors of MEK enzymes |
| 09/21/2005 | CN1219764C W-carboxyaryl substituted diphenyl ureas as RAF kinase inhibitors |
| 09/21/2005 | CN1219753C Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 09/21/2005 | CN1219556C The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| 09/21/2005 | CN1219551C Conjugates made of metal complexes and oligonucleotides |
| 09/21/2005 | CN1219537C Chinese medicine for treating leucocythemia and its preparation method |
| 09/21/2005 | CN1219525C Chinese medicine for treating women's ovary cancer and uterine myoma |
| 09/21/2005 | CN1219517C Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method |
| 09/21/2005 | CN1219516C Medical use of 11, 11'-dideoxy wotixilin |
| 09/21/2005 | CN1219509C Use of rosmarinic acid and derivatives thereof as immunosuppressant or inhibitor of SHz-mediated process |
| 09/20/2005 | US6946561 Desorption; reverse phase chromatography |
| 09/20/2005 | US6946558 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 09/20/2005 | US6946548 Granulocyte colony stimulating factor ("G-CSF") analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. |
| 09/20/2005 | US6946543 Truncated EGF receptor |
| 09/20/2005 | US6946484 Controlling cancer by reducing its growth and improving response to therapy |
| 09/20/2005 | US6946483 Aminoalkenylbenzoyl-benzofuran or benzothiophene, method for preparing same and compositions containing same |
| 09/20/2005 | US6946472 Polycyclic compounds exhibiting anti-tumor activities |
| 09/20/2005 | US6946471 2-(2,6-Dichlorophenyl)-Diarylimidazoles |
| 09/20/2005 | US6946468 that inhibit farnesylation of mutant ras gene products; cancer; (2)-2-(2-methoxy-ethyl)-1-((cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-4-naphthoyl-piperazine |
| 09/20/2005 | US6946467 Serine protease inhibitors |
| 09/20/2005 | US6946466 Aromatic sulfonamides as peroxynitrite-rearrangement catalysts |
| 09/20/2005 | US6946462 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents |
| 09/20/2005 | US6946456 Administering compounds which inhibit heat shock protein 90 proteins; methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction |
| 09/20/2005 | US6946455 Interstrand crosslinking agents for DNA and compounds therefor |
| 09/20/2005 | US6946454 Thio-oxindole derivatives |
| 09/20/2005 | US6946445 peptide antagonists of CXC chemokine receptor 4, CXCR4; cancer and autoimmune diseases; protein that comprises an N-terminal sequence of KGVSLSYR (SEQ ID NO: 3); stromal cell derived factor one (SDF-1 ligand |
| 09/20/2005 | US6946444 Modify the activity of the lipolysis stimulated receptor and can be used to influence the partitioning of dietary lipids between the liver and peripheral tissues; treating obesity-related insulin resistance |
| 09/20/2005 | US6946264 DNA codes for polypeptides having amino acid sequences used as metalloenzyme inhibitors, for prophylaxis of autoimmune diseases or as wound healing agents |
| 09/20/2005 | US6946259 Compositions and methods for treating cells having double minute DNA |
| 09/20/2005 | US6946244 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator |
| 09/20/2005 | US6946131 Comprises heparan sulfate proteoglyeans; antiproliferative agents |
| 09/20/2005 | US6946129 Recombinant anti-CD40 antibody and uses thereof |
| 09/20/2005 | CA2370692C Antitumor derivative of double dicarboxylic acid diaminoplatin complex, process for the preparing thereof, the pharmaceutical composition containing the same and application of the derivative |
| 09/20/2005 | CA2211668C Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing the same |
| 09/20/2005 | CA2124793C Use of creatine phosphate or phosphoenolpyruvic acid for the treatment of tumours |
| 09/15/2005 | WO2005085455A1 Compositions and methods for treating disease |
| 09/15/2005 | WO2005085264A1 Sulfated oligosaccharide derivatives |
| 09/15/2005 | WO2005085223A1 Composition for prevention and/or treatment of bone disease, functional food or health food containing the composition, and medicinal preparation containing the composition as active ingredient |
| 09/15/2005 | WO2005085215A1 Anticancer agent |
| 09/15/2005 | WO2005085210A1 Nitriles and medicinal compositions containing the same as the active ingredient |
| 09/15/2005 | WO2005085209A1 Basic amine compound and use thereof |
| 09/15/2005 | WO2005085201A1 Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein |
| 09/15/2005 | WO2005085200A1 Pyridone derivative |
| 09/15/2005 | WO2005085196A2 Inhibitors of dna methylation in tumor cells |
| 09/15/2005 | WO2005084708A1 Medicinal composition containing cxcr3 inhibitor |
| 09/15/2005 | WO2005084679A1 Composition containing benzamidine derivative and method for stabilizing benzamidine derivative |
| 09/15/2005 | WO2005084665A1 Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof |
| 09/15/2005 | WO2005084661A1 Antitumor agent |
| 09/15/2005 | WO2005077366B1 Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells |
| 09/15/2005 | WO2005027966A3 Antibodies with altered effector functions |
| 09/15/2005 | WO2005020900A3 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 09/15/2005 | WO2005018547A3 Mitotic kinesin inhibitors |
| 09/15/2005 | WO2005014777A3 Methods and compositions for increasing the efficacy of biologically-active ingredients |
| 09/15/2005 | WO2005013951A3 Pharmaceutical compositions for preventing breast and ovarian cancer |
| 09/15/2005 | WO2005009389A3 Anaplastic lymphoma kinase modulators and methods of use |
| 09/15/2005 | WO2004096792A3 Novel indole derivatives, method of preparing same in the form of medicaments, pharmaceutical compositions and, in particular, kdr inhibitors |
| 09/15/2005 | WO2004066922A3 A method of treating breast cancer with androgen receptor antagonists |
| 09/15/2005 | WO2004056307A3 Disease treatment via antimicrobial peptide inhibitors |
| 09/15/2005 | WO2004009112A8 Use of urease for inhibiting cancer cell growth |
| 09/15/2005 | WO2003085087A8 Modified cea nucleic acid and expression vectors |
| 09/15/2005 | WO2003000844A3 Protein modification and maintenance molecules |
| 09/15/2005 | US20050204412 Artery- and vein-specific proteins and uses therefor |
| 09/15/2005 | US20050203282 For screening of agonists and antagonists of receptor which may have advantageous pharmaceutical or diagnostical properties; for identification of patients who may present genetic disorders induced by inactive receptor |
| 09/15/2005 | US20050203181 Acyloxymethyl esters of C6-14 alkane-dicarboxylic acids, higher absorbtion of esters; does not induce bacterial resistance |
| 09/15/2005 | US20050203158 Substituted benzimidazole compounds |
| 09/15/2005 | US20050203153 Drugs with carriers as prodrugs for anticancer agents |
| 09/15/2005 | US20050203127 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 09/15/2005 | US20050203126 Inhibitors of basic fibroblast growth factors (FGFs); treating cancer, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, diabetic retinopathy, achondroplasia, hypochondoplasia, or thanathophoric dysplasia |
| 09/15/2005 | US20050203114 Pyrimidine-indole derivatives; cancer, autoimmunological, metabolic, inflammatory, infection (bacterial, viral, yeast, fungal, etc.), diseases of the central nervous system, degenerative neural disease, allergy/asthma, dermatology, angiogenesis, neovascularization, vasculogenesis, and cardiovascular |
| 09/15/2005 | US20050203109 Novel Compounds |
| 09/15/2005 | US20050203101 Benzimidazole quinolinones and uses thereof |
| 09/15/2005 | US20050203093 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/15/2005 | US20050203082 Administering with a carbamoylating agent such as BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea] and CCNU [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea]) to treat neoplastic disorders, such as glioblastoma multiforme; anticarcinogenic and antitumor agents; side effect reduction; brain cancer |
| 09/15/2005 | US20050203077 Selenophene anti-tumor agents |
| 09/15/2005 | US20050203060 Methods of using thalidomide in combination with irinotecan |
| 09/15/2005 | US20050203036 Compositions and methods for treating hematologic malignancies and multiple drug resistance |
| 09/15/2005 | US20050203003 Contulakin-G, analogs thereof and uses therefor |
| 09/15/2005 | US20050202559 Cancer treatment by metabolic modulations |
| 09/15/2005 | US20050202548 Mammalian enzymatic polypeptide for use as tool in designing drugs which prevent and treat hypercholesterolemia, hyperlipemia, arteriosclerosis, parasitic infection, cell proliferative and vascular diseases |
| 09/15/2005 | US20050202474 Phosphodiesterases |
| 09/15/2005 | US20050202454 "STRAP" and "STEAP"(six transmembrane (epithelial) antigen of the prostate) |
| 09/15/2005 | US20050202452 Assay determining the activity of an agent to decrease cell division; contacting protein capable of superoxide production with compound of interest and and measuring the ability of the agent to decrease superoxide production, inhibit diaphorase activity or bind the protein |
| 09/15/2005 | US20050202431 Coumpound for use in diagnosis and treatment of cell proliferative disorders; gene therapy; antitumor agents |
| 09/15/2005 | US20050202411 Preparing biopsy of tumorous tissue and monitoring chemosensitivity to anticarcinogenic agents; antitumor agents |
| 09/15/2005 | US20050202410 Precise efficacy assay methods for active agents inlcluding chemotherapeutic agents |